Nice one Wilbs
As opposed to the 2nd study of Kurtzberg
et al. (42), patient population in our study were highly pretreated and
refractory to previous treatments, which might have worsened
response.Some authors (42, 44, 49) have also showed that, when
MSCs were applied in an earlier stage of SR-aGVHD, the CR rates
were higher. For example, Le Blanc et al. (42), in their study of a
group of SR grade II-IV patients, described 55% CR and 16% PR.
For that reason, taking into account the side effects of second line
immunosuppression for GVHD and the good safety profile of MSCs
(even in severely affected children), earlier use of MSCs therapy
could be considered for patients with acute SR-GVHD.
Reg
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-17701
-
- There are more pages in this discussion • 339 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B |
Open | High | Low | Value | Volume |
92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 93.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.0¢ | 204239 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 0.930 |
6 | 79973 | 0.925 |
13 | 254982 | 0.920 |
11 | 107275 | 0.915 |
4 | 115328 | 0.910 |
Price($) | Vol. | No. |
---|---|---|
0.940 | 204239 | 3 |
0.945 | 22942 | 2 |
0.950 | 91123 | 5 |
0.955 | 42425 | 1 |
0.960 | 61820 | 3 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |